Close Menu
Chicago News Journal
    Facebook X (Twitter) Instagram
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Facebook X (Twitter) Instagram YouTube TikTok
    Chicago News JournalChicago News Journal
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • LifeStyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About us
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Privacy Policy
      • Terms and Conditions
    Chicago News Journal
    Home»US News

    Hims & Hers plummets 16% after first-quarter loss, weak guidance

    AdminBy AdminMay 12, 2026 US News
    Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram
    Hims & Hers plummets 16% after first-quarter loss, weak guidance

    Piotr Swat | Lightrocket | Getty Images

    Telehealth company Hims & Hers’ stock plummeted in early trading Tuesday after posting a first-quarter loss and weak earnings guidance for the year ahead.

    The digital health firm reported a net loss of $92 million in its first quarter earnings on Monday, compared with roughly $50 million for the same period the prior year. Its adjusted Ebitda was $44 million, down from $91 million last year. Meanwhile, revenue was up 4% to $608 million. Average monthly revenue per subscriber was $80, down from $85 last year.  

    Hims is expecting revenue in a range between $680 million and $700 million for the second quarter, and is forecasting up to $3 billion in revenue for the full year.

    It forecast adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) up to $55 million for the second quarter, and up to $350 million for the full year.

    The company’s stock was last trading down 15.7% in premarket trading.

    Stock Chart IconStock chart icon

    hide content

    Hims & Hers shares year to date.

    Citi analysts described the forecast as “mixed” and noted that Hims & Hers second-quarter outlook came in below Citi’s estimates.

    The analysts also flagged that the first quarter marks a “transition” phase for the company as it reduces its reliance on compounded GLP-1s.

    Hims reached a deal with Novo Nordisk in March to sell its GLP-1 weight loss drug Wegovy on its platform while committing to stop advertising cheaper copycat versions of the drug known as compounding drugs.

    Hims stock has often reacted strongly to any news that may affect its ability to sell weight loss drugs to consumers, which has been a highly profitable business for the telehealth company.

    Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

    Read the original article here

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    You might also be interested in...

    JPMorganChase reports cyberattack on third-party service providers

    November 19, 2026

    Musk regrets nearly $500 million midterm elections spending, says hes not MAGA

    November 19, 2026

    In historic move, House Democrats nominate Hakeem Jeffries for speaker of the House

    November 18, 2026

    Federal Reserve's Cook refuses to participate in White House hearing

    November 17, 2026

    The advice Biden got from Mitt Romney, and other takeaways from his memoir

    November 17, 2026

    Lindsay Clancy gets new trial date

    November 16, 2026
    Popular Posts

    How to tell a cyberattack from a plain old outage

    Movie Review: Elsinore

    Interview with Aletheia von Gottlieb, Author of Love Off the Ice (Sweet Snowfall Kisses Book 1) – NewInBooks

    What Were Wearing: Friendsgiving

    In historic move, House Democrats nominate Hakeem Jeffries for speaker of the House

    Book Riots Deals of the Day for November 18, 2026

    Categories
    • Books (2,457)
    • Business (3,449)
    • Events (34)
    • Film (1,062)
    • LifeStyle (2,922)
    • Music (2,796)
    • Politics (2,355)
    • Science (1,952)
    • Technology (1,817)
    • Television (3,628)
    • US News (3,294)
    Archives
    Useful Links
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Popular Posts
    • Top House China hawk to retire, opening seat in battleground WisconsinTop House China hawk to retire, opening seat in battleground Wisconsin
    • Same Same But Different: What Our Editors Are Wearing During Fashion Month
    • The Morning Report 10/2The Morning Report 10/2
    • 2026 Book Riot Audience Survey2026 Book Riot Audience Survey
    • Why it would be utter madness to stop funding mRNA vaccine technologyWhy it would be utter madness to stop funding mRNA vaccine technology
    Archives
    Categories
    • Books
    • Business
    • Events
    • Film
    • LifeStyle
    • Music
    • Politics
    • Science
    • Technology
    • Television
    • US News
    Facebook X (Twitter) Instagram YouTube TikTok
    © 2026 Chicago News Journal. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.